8-K: NeuroOne Reports Strong Gross Margin Improvement and FDA Submission for Facial Pain System

NeuroOne Medical Technologies Corporation announces improved financial results for Q2 fiscal year 2025 and the filing of an FDA submission for its OneRF Trigeminal Nerve Ablation System.

Summary

• NeuroOne Medical Technologies Corporation reported its financial results for the second quarter of fiscal year 2025, ended March 31, 2025.
• The company filed a 510(k) submission with the FDA for its OneRF Trigeminal Nerve Ablation System ahead of schedule, potentially generating revenue in late calendar year 2025 if cleared.
• NeuroOne completed an oversubscribed capital raise in April 2025, securing $8.2 million in net proceeds and is fully funded through at least fiscal year 2026.
• The company reaffirmed its fiscal year 2025 product revenue guidance of $8.0 to $10.0 million, excluding license revenue, representing a 132% to 190% increase compared to fiscal year 2024.
• Product revenue for the quarter was $1.4 million, consistent with the same quarter in the prior year, but first six months product revenue increased 98% to $4.7 million.
• The company also had license revenue of $3.0 million in the first six months of fiscal 2025 from its expanded agreement with Zimmer Biomet.
• Gross profit margin improved significantly to 55.6% in the second quarter, compared to 28.3% in the same quarter of the prior year.
• The net loss for the quarter improved to $2.3 million, or ($0.07) per share, compared to a net loss of $2.9 million, or $(0.11) per share, in the prior year.
• As of March 31, 2025, the company had cash and cash equivalents of $1.3 million and no debt outstanding.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the FDA submission, successful capital raise, and improved gross margin. However, the company is still operating at a loss, which tempers the overall sentiment.

Positives

• The company is fully funded through at least fiscal year 2026 following a successful capital raise.
• Gross margin has significantly improved year-over-year.
• The company is debt-free.
• Net loss has improved compared to the previous year.
• The company has secured significant media interest.

Negatives

• Cash and cash equivalents decreased slightly from September 30, 2024, to March 31, 2025.
• Product revenue was flat year-over-year for the second quarter.

Risks

• The company's future performance depends on FDA clearance of the Trigeminal Nerve Ablation System.
• The company's projections are subject to risks related to strategic partnerships, supply chain disruptions, and clinical trial outcomes.
• The company's ability to achieve its business objectives depends on its ability to raise additional funds if needed.

Future Outlook

The company expects product revenue for fiscal year 2025 to range between $8.0 million and $10.0 million, representing an increase of between 132% and 190% compared to fiscal year 2024. Product gross margin in fiscal year 2025 is expected to range between 47% and 51%, compared to 31% in fiscal year 2024.

Management Comments

• Dave Rosa, CEO of NeuroOne, stated that the second quarter was highlighted by significant operational progress with the OneRF Ablation System technology platform.
• Rosa believes there is a potential to generate revenues from trigeminal nerve ablation as soon as late calendar year 2025 if cleared by the FDA.
• Rosa mentioned discussions with strategic partners for applications leveraging the OneRF System, including spinal cord nerve ablation and spinal cord stimulation.
• Rosa concluded that the company has the necessary capital to execute on its strategic growth initiatives and several upcoming milestones that present significant opportunities to grow shareholder value.

Industry Context

NeuroOne is operating in the medical technology sector, focusing on minimally invasive solutions for neurological disorders. The company's partnerships with Zimmer Biomet and Mayo Clinic are significant, as they provide access to established distribution channels and clinical expertise. The focus on pain management and drug delivery aligns with growing market needs in these areas.

Comparison to Industry Standards

• NeuroOne's partnership with Zimmer Biomet is similar to other collaborations in the medical device industry, such as Medtronic's partnership with Mazor Robotics, which also focuses on robotic surgery.
• The company's focus on minimally invasive procedures aligns with the broader industry trend towards less invasive surgical techniques, which can reduce patient recovery times and healthcare costs.
• Compared to companies like Boston Scientific and Abbott, which have established positions in neuromodulation, NeuroOne is still in an earlier stage of commercialization, but its innovative electrode technology could provide a competitive advantage.
• The gross margin improvement to 55.6% is a positive sign, as it approaches the industry average for medical device companies, which typically ranges from 60% to 70%.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the increased revenue potential and improved financial performance.
• Patients may benefit from the new and improved treatment options for neurological disorders.
• Employees may benefit from the company's growth and expansion.

Next Steps

• Continue working with Zimmer Biomet on advanced training and education for the OneRF Ablation System.
• Pursue ISO13485 certification to commercialize outside of the United States.
• Continue discussions with potential strategic partners for the Percutaneous Paddle Lead and sEEG-Based Drug Delivery programs.
• Complete chronic animal study for the Spinal Cord Stimulation Percutaneous Paddle Lead Program.
• Complete drug delivery system in calendar 2025.

Key Dates

Keywords

NeuroOne, financial results, OneRF, trigeminal nerve ablation, FDA submission, capital raise, gross margin, neurological disorders, Zimmer Biomet, medical technology